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Abstract
Background: Malaria in pregnancy is characterized by accumulation of infected erythrocytes (IE) in the
placenta. The key ligand identified as mediating this process is a Plasmodium falciparum erythrocyte
membrane protein 1 family member, termed VAR2CSA. VAR2CSA appears to be the main ligand
responsible for adhesion to chondroitin sulphate A (CSA). Whether other PfEMP1 molecules can also
mediate placental adhesion, independent of CSA binding, is unclear.
Methods: The parasite line CS2 carrying a disrupted var2csa gene (CS2KO) was selected for adhesion to
the BeWo choriocarcinoma cell line, which has been proposed as a model for placental malaria. The
selected and control IE were tested for adhesion to placental sections and flow cytometry was used to
measure recognition of IE by three serum sets from malaria-exposed men and women.
Results: Wild-type CS2 adhere to BeWo and placental tissue via CSA. CS2KO IE were successfully
selected for adhesion to BeWo, and adhered by a CSA-independent mechanism. They bound to
immobilized ICAM-1 and CD36. BeWo-selected CS2KO bound at moderate levels to placental sections,
but most binding was to placental villi rather than to the syncytiotrophoblast to which IE adherence occurs
in vivo. This binding was inhibited by a blocking antibody to CD36 but not to ICAM-1. As expected, sera
from malaria-exposed adults recognized CS2 IE in a gender and parity dependent manner. In one serum
set, there was a similar but less pronounced pattern of antibody binding to selected CS2KO IE, but this
was not seen in two others. One var gene, It4var19, was particularly abundant in the selected line and was
detected as full length transcripts in BeWo-selected IE, but not unselected CS2KO.
Conclusion: This study suggests that IE with characteristics similar to the CS2KO have a limited role in
the pathogenesis of placental malaria. VAR2CSA appear to be the major ligand for placental adhesion, and
could be the basis for a vaccine against pregnancy malaria.
Published: 26 March 2008
Malaria Journal 2008, 7:51 doi:10.1186/1475-2875-7-51
Received: 12 November 2007
Accepted: 26 March 2008
This article is available from: http://www.malariajournal.com/content/7/1/51
© 2008 Yosaatmadja et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
Malaria Journal 2008, 7:51 http://www.malariajournal.com/content/7/1/51Background
Almost half of the world's population is exposed to the
risk of malaria infection, and despite current control
measures, more than one million people die annually.
Those who are at the greatest risk are pregnant women and
children under five years of age [1,2]. Pregnancy-associ-
ated malaria (PAM) is particularly frequent in women in
their first and second pregnancies [3]. PAM is character-
ized by the accumulation of mature stage parasites in the
intervillous space of the placenta [4,5]. This sequestration
contributes to adverse pregnancy outcomes such as mater-
nal anemia and low birth weight babies [2].
The accumulation of Plasmodium falciparum-infected
erythrocytes (IE) in the maternal placental intervillous
space is thought to be mediated by interactions between
members of the P. falciparum erythrocyte membrane pro-
tein 1 (PfEMP1) family of proteins expressed on the IE
surface and placental receptors such as chondroitin sulfate
A (CSA) and hyaluronic acid (HA) [6,7]. CSA is expressed
by the placental syncytiotrophoblast layer, which lines the
maternal blood spaces of the placenta [6,8]. PfEMP1 is
also the dominant parasite derived variant surface antigen
(VSA) expressed on IE, and immunity to placental malaria
has been correlated with development of immunity to a
PfEMP1 molecule, termed VAR2CSA (reviewed in [5]).
PfEMP1 is encoded by the var gene family. Switching of
var gene expression alters the PfEMP-1 displayed on the
red cell surface and may change the adhesion and anti-
genic phenotype of the IE, resulting in evasion of splenic
clearance [9,10]. The VAR2CSA PfEMP-1 has been linked
to the pathogenesis of malaria in pregnancy. Its transcrip-
tion is associated with adhesion to CSA and HA and with
placental malaria [11-14]. VAR2CSA recombinant
domains are recognized by IgG from residents in endemic
areas, in a gender specific and parity dependent manner
[15]. Following genetic disruption of var2csa there is little
or no binding to CSA [16,17]. It is presently unknown
whether VAR2CSA is the only molecule responsible for
placental infection. Other var genes can be detected in pla-
cental malaria [14], and unidentified placental receptors
appear to exist [18].
To determine whether other parasite ligands than
VAR2CSA mediate placental sequestration, a parasite line
with a targeted disruption of var2csa (CS2Δvar2csa,
referred to as CS2KO) [17] was selected for adhesion to
the BeWo human choriocarcinoma cell line [18-20].
CS2KO IE were then characterized for their ability to
adhere to human placental tissue and to individual lig-
ands, for the ability of sera from pregnant and non-preg-
nant adults to recognize the VSA they expressed, and for
expression of dominant var transcripts.
Materials and methods
Plasmodium and human choriocarcinoma (BeWo cells) 
culture
The P. falciparum CS2KO clone [17] and CS2 wild type
were cultured as previously described in RPMI-HEPES
supplemented with NaHCO3, gentamicin, and 0.5%
Albumax II (Gibco) [21]. Parasite line E8B was cultured
the same medium, but supplemented with 5% serum and
0.25% Albumax II. To sustain the expression of knobby
parasites, trophozoite-stage IE underwent weekly flota-
tion in 0.75% gelatin in RPMI-HEPES [22]. Parasites were
maintained in malaria gas mix (5% CO2, 1% O2 in N2).
The human choriocarcinoma-derived cell line BeWo was
a gift from Robin Mortimer (Placental Transport Unit,
QIMR, Australia). BeWo cells were cultured in RPMI 1640
(Invitrogen)-L-glutamine, supplemented with 10% fetal
bovine serum (Invitrogen), and 1% penicillin and strepto-
mycin solution. The cells were grown in a humidified
atmosphere in 5% CO2.
Selection of IE for adhesion to BeWo cells
To select CS2KO IE on BeWo cells, trophozoite-stage IE
were purified by flotation in 0.5% or 0.75% gelatin in
RPMI-HEPES, to 70–80% parasitaemia. The assays were
carried out in cytoadherence medium (RPMI-HEPES
pH6.8, supplemented with 10% human serum). BeWo
cells were grown to ~80% confluence in a tissue culture-
treated dish (Falcon, 150 × 22 mm) for up to 48 hr prior
the adhesion assays. The cells were washed once with
cytoadherence medium before selection. Purified IE were
resuspended, and co-incubated on BeWo cells for 45 min-
utes at 37°C in the malaria gas mixture. Unbound cells
were gently washed off with RPMI-HEPES, and bound IE
detached by aspiration with parasite culture medium
directly onto BeWo cells. Detached IE were then returned
to culture with fresh erythrocytes. After each round of
selection, IE were grown to ~6–8% parasitaemia, and
binding levels were evaluated before reselection. This
cycle was repeated ten times on BeWo cells.
Cytoadherence to BeWo cells
To evaluate adhesion, IE at 1% haematocrit and 6–8%
parasitaemia in cytoadherence medium were added to
triplicate wells of BeWo cells (~80% confluent) cultured
in 6-well plates, with or without 10 μg/ml of bovine tra-
chea CSA (Sigma). After 45 min of co-incubation in
malaria gas mix at 37°C, unbound cells were removed by
gentle washing with RPMI-HEPES, pH6.8. Bound IE were
fixed using 2% glutaraldehyde and stained with Giemsa
(Merck). The mean (± SEM) number of adherent IE per
100 BeWo cell nuclei was determined in two independent
experiments, by counting under oil immersion (100 ×
magnification).Page 2 of 10
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(15.2, Serotec) on IE adhesion to BeWo, 8–10 mm diam-
eter wells were created in 6 well plates using a wax pen
(Dako) prior to plating. When BeWo cells reached
70–80% confluency they were then co-cultured with IE at
6–8% parasitaemia in cytoadherence medium, with or
without anti-ICAM-1 antibody at 10 μg/ml, and experi-
ments performed as described above.
Adhesion to immobilized receptors
Adhesion to purified receptors was carried out as previ-
ously described [21,23]. Purified receptors used were
bovine trachea CSA (Sigma), CD36 (R&D Systems),
ICAM-1 (Bendermed Systems), human chondroitin sul-
phate proteoglycan (purified from placental blood;
Malaria Research and Reference Reagent Resource
Center), HA (from bovine vitreous humour; Sigma) and
Fibrinogen (from human plasma; Calbiochem). These
receptors were immobilized on plastic Petri dishes (150
mm-diameter, Falcon 1058) as previously described, with
some minor adjustments [21]. Briefly, three spots con-
taining selected receptors were blocked with casein (Pierce
Biotechnology, Rockford IL) for 30 min at RT, and then
washed twice with PBS before adding IE diluted in cytoad-
herence medium (6–8% parasitaemia and 2% haemat-
ocrit). Cultures were incubated at 37°C in a moist box for
45 min, then unbound erythrocytes were removed by gen-
tle washing with RPMI-HEPES. After fixing in 2% glutaral-
dehyde and staining with Giemsa, the number of
adherent IE/mm2 was determined in two to three inde-
pendent experiments, by counting under oil immersion
(100 × magnification).
Adhesion to frozen placental sections
Adhesion assays on ex vivo placental tissue were per-
formed as described previously [24]. Briefly, gelatin-puri-
fied trophozoite-stage IEs, that had been grown in RPMI
1640 containing 0.5% Albumax II, were resuspended at 5
× 106 IE/ml in cytoadherence medium. IE were incubated
at room temperature on unfixed sets of three consecutive
5-μm cryosections of normal human placenta. Adhesion
was carried out for 1 h, with agitation every 20 min, fol-
lowed by gentle washing in RPMI 1640 (pH 6.8) to
remove unbound IE. CS-specific adhesion was deter-
mined by pre-incubating placental tissue with 0.5 units/
ml chondroitinase ABC (cABC; Fluka) for 30 min at 37°C,
washing three times in RPMI 1640 (pH 6.8), and then
adding IE. Specific adhesion to CSA was tested by pre-
incubating IE with 100 μg/ml CSA for 15 minutes prior to
incubating on placental tissue. Adhesion to CD36 or
ICAM-1 was tested by pre-incubating placental sections
with 0.5 μg/ml anti-CD36 antibody (FA6/152; Beckman
Coulter) or 10 μg/ml anti-ICAM-1 antibody. Following
adhesion assays, sections were fixed in 2% glutaralde-
hyde, stained with Giemsa, and the average number of IE
(± SEM) per field (10 fields per well) was determined
using a 40 × objective. IE adhesion within the intervillous
space, directly to syncytiotrophoblast, or within the foetal
villous tissue was determined for at least three independ-
ent cryosections (sourced from two different placentas).
In each case, binding of IE was compared to IE adhesion
on an untreated control section present on the same slide.
Placental tissue was obtained with approval from the
Mater Human Research Ethics Committee, Brisbane, Aus-
tralia, after informed written consent.
Sample collection
Serum and plasma samples were collected from pregnant
women and men who lived in Blantyre, Malawi or
Madang, Papua New Guinea, with informed consent from
donors. Three sets of samples were tested. Cohort-one
comprised sera collected in late third trimester of preg-
nancy from HIV uninfected, malaria infected pregnant
women from Queen Elizabeth Central Hospital, Blantyre,
collected in 2002–4 [25]. Samples from male patients
were from fathers of children admitted to the same hospi-
tal with severe malaria [21]. Cohort-two comprised unse-
lected pregnant women and men attending outpatient
clinics at Modilon Hospital, Madang, collected in 2001–2
[26]. Cohort-three comprised plasma from pregnant
women collected at delivery in Blantyre, Malawi, and sam-
ples again from fathers of children admitted to the same
hospital with severe malaria, collected in 1997–9 [27].
Negative control sera were collected from Australian
blood donors. The collection and use of these samples
were approved by the College of Medicine Research Com-
mittee, University of Malawi, the Papua New Guinea Med-
ical Research Advisory Committee, and the Clinical
Research Ethics Committee, Royal Melbourne Hospital
Research Foundation, Victoria, Australia.
Flow cytometry
Flow cytometry to measure antibodies against VSA
expressed by IE was carried out according to our previ-
ously described method [27]. Trophozoite stage IE (6–8%
parasitaemia, 0.1% haematocrit) were incubated with
serum at 1/20 dilution, washed, then incubated with rab-
bit anti-human IgG (DAKO) and Alexa Fluor 488-conju-
gated anti-rabbit IgG. Parasite nucleic acid was stained
with ethidium bromide (10 μg/ml). Samples were washed
three times after each step, and assayed using a BD FACS-
calibur flow cytometer. The level of specific IgG staining
was calculated by subtracting the mean fluorescence
intensity (MFI) of uninfected erythrocytes from the MFI of
the IE [17]. Non-parametric one way ANOVA statistical
analysis was used.
Quantitative RT PCR and Northern Blot
RNA from synchronized ring stage IE ~4–8 hr post inva-
sion was extracted using Trizol reagent (Invitrogen). [28].Page 3 of 10
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Turbo DNase (Ambion). cDNA synthesis was performed
using Superscript III reverse transcriptase (Invitrogen).
PCR was performed to amplify cDNAs using previously-
published degenerate nucleotides derived from conserved
sequences within var gene DBL α [29] and DBL β [30]
domains. Primers used were DBLα forward GGinosineG-
CinosineTG(C/T)GCinosineCC(A/G)T(A/T)(C/T)(A/
C)G; DBLα reverse TCTTCinosineG(C/T)CCATTCCTC-
GAACCA; DBLβ forward (DBL_5.3) G(T/A)(C/
G)AACA(T/C)(A/T)T(G/T)TGTAC(A/C)TC; DBLβ reverse
(DBL_3.2) AATC(G/T)TTG(A/G/T)GG(A/G)AT(A/
G)TA(A/G)TC. PCR products were cloned and 20 clones
of each product were sequenced.
Absolute quantitation of the cDNAs of the two var genes
identified by cloning was performed by Q-RT-PCR using
standard curves of plasmids containing var gene
sequences as previously described [13]. Quantitation of
18S rRNA was used to normalize parasite cDNAs and
employed the primers GCTGACTACGTCCCTGCCC and
ACAATTCATCATATCTTTCAATCGGTA and standard
curves of diluted parasite gDNA. The primers used for Q-
RT-PCR of the cloned var genes were IT4var44 (forward
TGCTTCATATTTTCGACCAACGT and reverse CAGCG-
GCATCGGTTTTG) at 6 μM and IT4var19 (forward TGA-
TAAATCTGCAATTTGTAATGCTATG and reverse
CCAAGGTCGGCGAAACTATATT) at 2 μM concentra-
tions. In addition, var2CSA-specific primers were used as
described (forward GGATTGACCACACCGTCTTCTT and
reverse TGTCCGCGCCACATATGT) at 2 μM. DNAse-
treated RNA of CS2KO9 was used as a negative control for
all quantitative RT-PCR runs. cDNAs were normalized
against quantitation of 18S RNA.
Northern blots, performed as described previously [13],
were hybridized at 55°C with radiolabelled probes
derived from IT4var19 DBLβ and var exon2 sequences.
The blots were washed twice at 55°C with 2 × SSC 0.1%
SDS (exon 2) or at 60°C with 0.5 × SSC 0.1% SDS prior to
exposure to film. Probed blots were stripped with boiling
0.5% SDS and absence of signal confirmed by exposure to
film prior to re-probing.
Results
Selection for adhesion of IE to BeWo cells
CS2 IE bound at high levels to BeWo cells ((343 ± 54
(SEM) IE/100 BeWo) and, as expected [31], binding was
inhibited by more than 70% by free CSA (85 ± 36 IE/100
BeWo). By contrast, IE of the var2csa knockout CS2
(CS2KO) bound at low levels to BeWo cells (Figure 1),
even after five rounds of panning selection. After repeated
cycles of selection on BeWo, adhesion of CS2KO
increased; after seven cycles adhesion reached a plateau at
120–150 IE per 100 BeWo nuclei (Figure 1). Adhesion
was not CSA-dependent, and was around half that of CS2
adhesion to BeWo (145 ± 9; 159 ± 14/100 BeWo nuclei
for the selected CS2KO in absence and presence of CSA,
respectively). For subsequent characterization CS2KO
selection 9 IE (termed CS2KO9) were used.
Adhesion of CS2KO selected line to immobilized receptors 
and placental tissue
The adhesion of CS2 and CS2KO9 IE to purified receptors
immobilized on plastic was determined. The adhesion
profile of CS2 IE was similar to that previously published
(Figure 2a) [7,17,32], whereas CS2KO9 IE adhered to
ICAM-1, and to a lesser extent to CD36, with minimal
binding to CSA, and none to CSPGs (Figure 2b). Thus,
disruption of var2csa changes the adhesion profile away
from the major placental malaria receptor (CSA), and
selection on BeWo does not restore this profile.
To determine whether CS2KO9 IE which adhered to
immobilized ICAM-1 also adhered to ICAM-1 on BeWo
cells or placental sections, a blocking antibody to ICAM-1
was used. ICAM-1 did not appear to be a major mediator
of adhesion to BeWo (CS2KO9, 124.1 (+/- 59.5) IE per
100 BeWo nuclei; CS2KO9 + 10 μg/ml anti-ICAM-1,
125.1 (+/- 47.2) IE per 100 BeWo nuclei). Moreover, the
parasite line E8B (which adheres at high levels to soluble
ICAM-1) bound to BeWo at low levels (31.0 (+/- 4.0) IE
per 100 BeWo nuclei).
To evaluate whether CS2KO9 might represent a parasite
type able to sequester in the placenta in a CSA-independ-
Adhesion of CS2KO IE to BeWo cells following repeated cycl s f selectionFigure 1
Adhesion of CS2KO IE to BeWo cells following repeated 
cycles of selection. Adhesion is expressed as IE bound per 
100 BeWo nuclei, in the presence (black bars) or absence 
(white bars) of CSA 10 μg/ml. Data shown are the mean + 
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cental tissue sections was investigated [33]. CS2 IE bound
to both the intervillous space and the placental syncytio-
trophoblast and this binding was inhibited by free CSA
and chondroitinase ABC treatment of tissue, consistent
with the known distribution of CSA in placenta [8] (Fig-
ure 3a). CS2KO9 bound at low levels to both IVS and SCT,
and this binding was not inhibited by CSA or chondroiti-
nase ABC (Figure 3a). Adhesion to accessible sites was
about 30% of that for CS2 IE, however binding of
CS2KO9 IE was predominantly to fetal villous tissue,
which is not accessible to IE in vivo. This binding may be
mediated by CD36, which is known to be expressed in
fetal villous tissue [34], as it was significantly inhibited by
a blocking antibody to CD36 (Figure 3b). Anti-ICAM-1
did not affect binding of CS2KO9 to placenta (Figure 3c),
however binding of a control ICAM-1 binding IE line
(E8B), which adheres to the villi and at low levels on the
syncytiotrophoblast, was inhibited by anti-ICAM-1 block-
ing antibody, but not free CSA (Figure 3c).
Antibodies to CS2KO selected line among pregnant 
women and men
Variant surface antigens (VSA) of placental and CSA
adherent IE are recognized by sera and plasma from preg-
nant women in a gender and gravidity-dependent man-
ner. The ability of sera or plasma to recognize CS2 and
CS2KO9 IE was assessed, using two cohorts from Malawi
and one from Papua New Guinea. For CS2 IE, each cohort
showed gender and parity-dependent recognition,
although not all differences were statistically significant
(Figure 4a,d and 4f). Cohort-one (Figure 4a) showed
marked gender and parity dependent recognition of CS2,
cohort-three showed significant gender-dependent
changes, and cohort-two showed similar trends. A similar,
but less pronounced, pattern was seen for CS2KO9 with
the first Malawi cohort tested (Figure 4b), but not for E8B
which adheres to ICAM-1 and CD36 receptors, but not
CSA (Figure 4c), prompting us to test other cohorts. Nei-
ther of these showed significant differences by gender or
parity in recognition of CS2KO9 (Figure 4e and 4g). We
conclude that gender and parity dependent recognition of
CS2KO9 occurs uncommonly, and that VSA of CS2KO9
are not prominent targets of pregnancy-specific immu-
nity. The pattern of recognition seen is in keeping with
that for other CD36 or ICAM-1 adherent isolates [21].
Var gene expression by CS2KO selected line
Var genes encode PfEMP-1 members, which mediate
adhesion to host receptors such as CSA, ICAM-1 and
CD36. To investigate whether selection on BeWo cells had
resulted in selection for expression of a particular var gene,
or group of var genes, we analysed RNA from CS2KO
unselected and CS2KO9 BeWo selected parasites by
Northern blot (Fig 5a). A conserved var exon 2 probe that
hybridizes to most var transcripts hybridized to a larger
transcript(s) in CS2KO9 than in CS2KO indicating that
this larger transcript(s) encoded the BeWo adhesion phe-
notype. To determine which var gene(s) are expressed by
CS2KO9, we used RT-PCR amplification of DBLα and
DBLβ var gene domains to identify transcripts of two var
genes, It4_var19 (accession EF158075) and It4_var44
(accession EF158091) (Figure 5) in CS2KO9 parasites. We
then used Q-RT-PCR to quantitate levels of transcription
of It4_var19, It4_var44 and var2csa in unselected CS2KO,
and CS2KO9. Transcripts of var19 were much more abun-
dant in CS2KO9 than CS2KO unselected parasites. The
dominance of It4_var19 in CS2KO9 was confirmed by its
co-migration with the most abundant var transcripts in
CS2KO9, identified by hybridization with the conserved
exon 2 probe (Figure 5a). These data indicated that expres-
sion of It4_var19 contributed to the CS2KO9 phenotype
of adhesion to BeWo. Transcripts of It4_var44 were only
marginally more abundant in CS2KO9 than in CS2KO
unselected parasites, indicating that expression of
It4_var44 was not important for the BeWo adhesion phe-
Adhesion of (a) CS2 IE and (b) CS2KO9 IE to immobilized recept rs, expressed as IE bound/mm2Figure 2
Adhesion of (a) CS2 IE and (b) CS2KO9 IE to immobilized 
receptors, expressed as IE bound/mm2. Data shown are the 
mean + SEM of two or more independent experiments, per-
formed in triplicate. CSA, chondroitin sulphate A; CSA+10 
μg/ml, Adhesion to CSA in presence of free CSA at 10 μg/ml; 
HCSPG, human chondroitin sulphate proteoglycan; ICAM-1, 
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var2csa.
Discussion
Placental malaria is a distinct form of the disease. Unlike
IE infecting non-pregnant individuals, IE isolated from
the placenta generally have a highly conserved phenotype
(adhesion to CSA), and predominantly transcribe one var
gene, termed var2csa [6,11,12,14,21]. Antibodies that
develop naturally in pregnant women cross-react in block-
ing adhesion of placental isolates from different regions
to CSA, suggesting conserved epitopes may mediate pro-
tection [35]. Var2csa appears to be the most important
gene encoding adhesion to CSA and HA; targeted disrup-
tion of var2csa ablated adhesion to CSA, and after
repeated panning little or no CSA adhesion was regained
[16,17].
PfEMP1 family members other than VAR2CSA, or differ-
ent proteins, might also mediate placental adhesion, and
IE might accumulate in the placenta by adhering to other
ligands expressed on the SCT. To investigate this possibil-
ity, CS2KO IE were selected by repeated panning on the
BeWo trophoblast cell line, which has been shown to be a
useful in vitro model of IE adhesion to SCT [18-20,31].
CS2KO IE selected on BeWo gradually increased adhesion
to BeWo, which reached a plateau after 7 cycles of pan-
ning. Adhesion of selected CS2KO IE remained lower
than that of wild type CS2 IE despite repeated cycles of
selection, and adhesion was not CSA-dependent. Instead,
CS2KO9 IE adhered to ICAM-1, which is known to be
expressed on SCT and BeWo cells and upregulated in
malaria infection [34]. Importantly, in clinical studies pla-
cental IE do not adhere to ICAM-1 [6,21]. Many parasite
isolates from children adhere to ICAM-1 [36,37], and
adults frequently have antibodies to VSA expressed by
such isolates [21], so host immunity may prevent them
from establishing infection in pregnant women. ICAM-1
did not appear to be the principal ligand for CS2KO9 IE
on BeWo as parasite line E8B, which binds to ICAM-1 and
CD36 but not to CSA or HA, adhered to BeWo at signifi-
cantly lower levels than CS2KO9, and a blocking antibody
to ICAM-1 did not significantly decrease adhesion of
CS2KO9 to BeWo.
On unfixed snap-frozen placental tissues (Figure 3)
CS2KO9 bound at low levels in the intervillous space and
to the SCT compared to CS2, and also bound to villous tis-
sue (to which IE have no access in vivo), probably using
CD36 as a ligand. Adhesion of CS2KO9 was not inhibited
by a blocking antibody to ICAM-1. Normal, uninfected
placental tissue was used, and it is possible that placental
malaria results in induction of expression of other parasite
receptors on villi or secreted into the intervillous space.
Nevertheless, the present findings suggest that CS2KO IE
Adhesion to human placental tissue cryosectionsFigure 3
Adhesion to human placental tissue cryosections. Adhesion 
levels of IE in the intervillous space (IVS), to syncytiotro-
phoblast (SCT) and over the villus (V) is shown compared to 
untreated (control) sections present on each slide. (a) Adhe-
sion of CS2 (white bars) and CS2KO9 (black bars) IE in the 
presence of CSA (100 μg/ml) or following chondroitinase 
ABC pretreatment (cABC) (0.5 units/mL). (b) Adhesion of 
CS2 (white) and CS2KO9 (black bars) IE in the presence of 
CSA or following anti-CD36 pre-treatment (0.5 μg/ml). (c) 
Adhesion of E8B (white) and CS2KO9 (black) IE in presence 
of CSA or following pretreatment with anti-ICAM-1 (10 μg/
ml). Adhesion was counted at 40× magnification and 








IVS SCT V IVS SCT V IVS SCT V 


























IVS SCT V IVS SCT V IVS SCT V 


























IVS SCT V IVS SCT V IVS SCT V 





















C Page 6 of 10
(page number not for citation purposes)
Malaria Journal 2008, 7:51 http://www.malariajournal.com/content/7/1/51
Page 7 of 10
(page number not for citation purposes)
IgG recognition by sera from malaria-exposed individualsFigure 4
IgG recognition by sera from malaria-exposed individuals. (a) CS2 (b) CS2KO9 and (c) E8B IE were incubated with sera from 
Malawian men, primigravid and multigravid women (cohort 1). (d) CS2 and (e) CS2KO9 IE were incubated with sera from men, 
primigravid and multigravid women from Madang, Papua New Guinea (cohort 2). (f) CS2 and (g) CS2KO IE were incubated 
with sera from men, primigravid, and multigravid women from Malawi (cohort 3). Data presented are mean fluorescence inten-
sities (MFI) for individual samples. Bars indicate median MFI for the population. Significant differences in responses were found 
as follows: (a) cohort 1, CS2: men and primigravidae (PG; p < 0.0001), men and multigravidae (MG; p < 0.0001) and PG and 
MG (p = 0.001); (b) cohort 1, CS2KO9: men and PG (p = 0.0011), men and MG (p < 0.0001), and PG and MG (p = 0.047); (c) 
cohort 1, E8B: men and MG (p = 0.047) (f) cohort 3, CS2, men and PG (p = 0.001), men and MG (p = 0.0013).
Malaria Journal 2008, 7:51 http://www.malariajournal.com/content/7/1/51selected on BeWo bind at low levels to available placental
ligands, and that VAR2CSA mediated adhesion is the
major driving force behind placental sequestration.
Recently, Viebig et al used the FCR3 parasite line with dis-
rupted var2csa[16,17] to study adhesion of FCR3KO para-
sites to BeWo cells, in experiments similar to those
reported here [38]. The overall conclusion was similar,
that an intact var2csa gene appears essential for IE to show
a pregnancy malaria phenotype, but there were some dif-
ferences in findings. Like CS2KO, the FCR3KO parasites
showed some ICAM-1 adhesion; but unlike CS2KO, adhe-
sion to BeWO was partly blocked by anti-ICAM-1. This
may be because several var genes (at least two abundantly
transcribed) were detected in the FCR3KO, whereas by
reverse transcription and by Northern blot, we detected a
single, different var in CS2KO, termed var19. FCR3KO
parasites selected on BeWo were not recognized in a par-
ity-dependent manner by immune sera, whereas one of
our sera sets showed parity dependent recognition of
CS2KO, and we saw low levels of adhesion of CS2KO.
Neither isolate showed significant specific adhesion to
SCT. Together these data suggest that IE panned on BeWo
may bind to multiple receptors, but that these are not nec-
essarily relevant to the pathogenesis of placental seques-
tration or pregnancy malaria.
Gender and parity dependent antibody responses develop
in pregnant women, which are directed against VSA
expressed by placental or CSA binding IE [39]. These
responses have been associated with protection from
anaemia, premature birth and low birth weight babies in
some studies [40,41]. If IE with a phenotype similar to
CS2KO9 are an important cause of placental malaria, then
a similar pattern of antibody responses would be
expected. By flow cytometry, typical gender and parity
dependent responses to CS2 were observed in samples
from Malawian and Papuan New Guinean men and
women, as expected. CS2KO9 IE were frequently recog-
nized by malaria exposed adults. In one series, similar
gender and parity-dependent trends were observed for
responses to CS2KO9, but there was no evidence of these
in the other series. It is possible that the gender and parity
dependent recognition we observed for CS2KO9 reflects
the ability of similar variants to elicit pregnancy-specific
immunity under certain circumstances. These data suggest
that variants expressing similar VSA to It4var19 could be a
minor cause of malaria in pregnancy in some cases, but
they contribute little to placental sequestration. It4var19
may determine the phenotype of CS2KO9. The receptor
for CS2KO9 IE adhesion to BeWo remains unknown.
Conclusion
The findings presented here support the central role of
var2csa in placental P falciparum infection. When IE lack-
ing var2csa were selected for adhesion to the BeWo chori-
ocarcinoma cell line, levels of binding to BeWo and to
placental tissue sections were significantly lower than
those seen with CS2 IE, which transcribe var2csa at high
(a) Northern blot analysis of CS2KO9 and CS2KO consecu-tively probed with IT4var19 and var exo  two sequences exon2)Figure 5
(a) Northern blot analysis of CS2KO9 and CS2KO consecu-
tively probed with IT4var19 and var exon two sequences 
(exon2). (b) Quantities of different var gene transcripts in 
BeWo selected CS2KO9 and unselected CS2KO parasites. 
Absolute quantification of var gene transcripts was per-
formed by quantitative RT-PCR using standard curves of 
plasmids containing the var gene target sequences. Presented 
data is normalized against 18S rRNA levels so that molecules 
of var cDNA from equivalent numbers of cells for each para-
site line are compared. Data are presented as mean + stand-
ard deviation.Page 8 of 10
(page number not for citation purposes)
Malaria Journal 2008, 7:51 http://www.malariajournal.com/content/7/1/51levels, and CS2KO9 IE were not recognized by human sera
in a pronounced gender and parity-dependent manner.
Variants similar to CS2KO9 frequently circulate in
malaria-exposed populations (as demonstrated by fre-
quent presence of antibody in both men and women), but
responses to such variants are only occasionally preg-
nancy-specific. These results further support var2csa as a
candidate for vaccine development against malaria in
pregnancy.
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